Search

Fagofarma, a Czech microbiological and pharmaceutical company, has been authorized by the Czech State Institute for Drug Control to produce GMP phages for clinical use, making it the second Czech company to do so.

Canadian phage therapy biotech Cytophage Technologies and Cuspis Capital III Ltd. have announced a business combination agreement and concurrent financing. This means additional funds for Cytophage as it develops phage therapy for human and

Armata Pharmaceuticals will present positive topline data from the SWARM-P.a. clinical study at the North American Cystic Fibrosis Conference November 3rd in Phoenix, AZ, highlighting results of their novel inhaled multi-phage therapeutic f

UK-based phage biotech company Fixed Phage has changed its name to NexaBiome Limited, to reflect its new focus as an end-to-end phage company in the human and animal health sectors.

Intralytix, Inc. has been issued a patent by the European Patent Office for several Shigella phages and their applications and formulations.

UCSD will soon open as a clinical trial site for Adaptive Phage Therapeutics' ACTIVE.2 trial, studying the safety and efficacy of APT's Phage Bank versus placebo in patients with prosthetic joint infections.

The first patient in Armata Pharmaceuticals’ newest trial has been treated. This is part of the Phase 2a portion of their diSArm study, which evaluates the potential treatment of S. aureus bacteremia.

Parallel Health, a new US phage skincare company, has announced $2.3M in funding and launched a custom phage therapy skin serum that targets bacteria causing skin conditions, offering personalized treatments based on individual skin microbi

Contrafect, a company developing ‘direct lytic agents’ (which include lysins and amurin peptides), has submitted an IND application for preliminary approval of a new IV antibacterial agent for treatment of hospital-acquired and ventilator-a

Intralytix has announced the launch of a Phase 1/2a clinical trial of its VRELysin™ phage preparation to assess safety and efficacy in healthy and VRE-colonized subjects at UPMC in Pittsburgh, Pennsylvania.

A new Canadian phage CRO, Qeen Bio is offering a variety of services including phage characterization, cell banking, fermentation, downstream processing, formulation, lab services for phage clinical trials, and regulatory consulting for pha

Cytophage Technologies has announced a distribution agreement with a leading animal health company in South Asia. The initial product for distribution will be Cytophage’s FARMPHAGE (TM) formulation for the poultry industry.

Adaptive Phage Therapeutics has entered into a collaboration and license agreement with the Israeli Phage Therapy Center of the Hebrew University of Jerusalem and Hadassah Medical Center. The agreement grants APT exclusive rights to make, u

PhageLab is a Chile-based AI-powered phage biotech company selling phage biocontrol to livestock producers. Their technology is a deep epidemiological analysis algorithm that identifies phages to match target bacteria, based on unique data

The UK phage biotech company, Fixed Phage, has appointed Dr Neil Clelland as its new CEO, along with a new COO and Executive Chairman. The company is looking to build on its position in the phage industry and provide innovative solutions fo

A new phage therapy company has launched! Phiogen is a spinoff from Baylor College of Medicine, located at Texas Medical Center's Innovation Hub. Based on TAILOR Labs’ phage therapy work, and building on patented technology for evolving pha

Fixed Phage has shown that their technology, which stably immobilizes phages to excipients, can efficiently treat acne when immobilized onto nylon beads and delivered through a cream, reducing the bacterial load on the skin.

Copenhagen-based SNIPR Biome, a CARB-X portfolio company, has developed SNIPR001, a cocktail of CRISPR-armed phages designed to target E. coli. A recent release by Robin Berghaus of CARB-X highlights the potential of SNIPR001 to prevent blo

Armata Pharmaceuticals announces positive topline data from the completed Phase 1b2a SWARM-P.a. trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in c

Boston-based global health startup PhagePro has obtained an exclusive license to develop and market their phage cocktail product to prevent community spread of cholera.